CINXE.COM

<!DOCTYPE html><html data-wf-domain="www.ascilion.com" data-wf-page="6458de8ba582e396f8939b64" data-wf-site="5a2e5fada298f500011268d5"><head><meta charset="utf-8"/><title>Ascilion</title><meta content="Sampling of dermal Interstitial Fluid (dISF) – Pioneering Hollow Microneedles – Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF). Access to endogenous and exogeneous biomolecules in dISF represents a unique opportunity for analysis of vital markers, health conditions and research. Bringing biomolecules out of the body and into analysis is paramount for the next step within life science." name="description"/><meta content="Ascilion" property="og:title"/><meta content="Sampling of dermal Interstitial Fluid (dISF) – Pioneering Hollow Microneedles – Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF). Access to endogenous and exogeneous biomolecules in dISF represents a unique opportunity for analysis of vital markers, health conditions and research. Bringing biomolecules out of the body and into analysis is paramount for the next step within life science." property="og:description"/><meta content="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6461e0507951b1100b447c58_social1200px-13.jpg" property="og:image"/><meta content="Ascilion" property="twitter:title"/><meta content="Sampling of dermal Interstitial Fluid (dISF) – Pioneering Hollow Microneedles – Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF). Access to endogenous and exogeneous biomolecules in dISF represents a unique opportunity for analysis of vital markers, health conditions and research. Bringing biomolecules out of the body and into analysis is paramount for the next step within life science." property="twitter:description"/><meta content="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6461e0507951b1100b447c58_social1200px-13.jpg" property="twitter:image"/><meta property="og:type" content="website"/><meta content="summary_large_image" name="twitter:card"/><meta content="width=device-width, initial-scale=1" name="viewport"/><meta content="NVHdyLU8mHEgDs1oi58Pt75xrvdtL9ko5jETVYSw-cU" name="google-site-verification"/><meta content="Webflow" name="generator"/><link href="https://assets-global.website-files.com/5a2e5fada298f500011268d5/css/ascilion.webflow.450617b11.css" rel="stylesheet" type="text/css"/><link href="https://fonts.googleapis.com" rel="preconnect"/><link href="https://fonts.gstatic.com" rel="preconnect" crossorigin="anonymous"/><script src="https://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js" type="text/javascript"></script><script type="text/javascript">WebFont.load({ google: { families: ["Open Sans:300,300italic,400,400italic,600,600italic,700,700italic,800,800italic","Lato:100,100italic,300,300italic,400,400italic,700,700italic,900,900italic","Roboto:300,regular,500"] }});</script><script type="text/javascript">!function(o,c){var n=c.documentElement,t=" w-mod-";n.className+=t+"js",("ontouchstart"in o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+=t+"touch")}(window,document);</script><link href="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/5a2e9f707cc425000195188b_fav.jpg" rel="shortcut icon" type="image/x-icon"/><link href="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/5a2e9fbda298f5000112b457_weblarge.jpg" rel="apple-touch-icon"/> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-KJMMWVVG');</script>  <style type="text/css"> @media screen and (min-width: 1350px) { .w-container { max-width: 1350px; } } </style> <meta name="google-site-verification" content="NVHdyLU8mHEgDs1oi58Pt75xrvdtL9ko5jETVYSw-cU" /> </head><body class="body"><div data-w-id="8fc2c70b-9445-059e-9a99-47516183c453" data-animation="default" data-collapse="medium" data-duration="400" data-easing="ease" data-easing2="ease" role="banner" class="navbar w-nav"><div class="navbar-container w-container"><a href="/" aria-current="page" class="logotype-link w-nav-brand w--current"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/645b62ec8c124f1151141509_ascilion_white.svg" loading="lazy" alt="" class="logotype-top"/></a><nav role="navigation" class="nav-menu w-nav-menu"><a href="/" aria-current="page" class="nav-link w-nav-link w--current">Home</a><a href="/products" class="nav-link w-nav-link">Products</a><a href="/technology" class="nav-link w-nav-link">Technology</a><a href="/applications" class="nav-link w-nav-link">Application areas</a><a href="/about" class="nav-link w-nav-link">About us</a><a href="/contactus" class="nav-link w-nav-link">Contact</a></nav><div class="menu-button w-nav-button"><div class="w-icon-nav-menu"></div></div></div></div><div data-poster-url="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-poster-00001.jpg" data-video-urls="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-transcode.mp4,https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-transcode.webm" data-autoplay="true" data-loop="true" data-wf-ignore="true" class="hero-video w-background-video w-background-video-atom"><video id="54603bef-1da3-50a3-147b-f51daac53ffe-video" autoplay="" loop="" style="background-image:url("https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-poster-00001.jpg")" muted="" playsinline="" data-wf-ignore="true" data-object-fit="cover"><source src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-transcode.mp4" data-wf-ignore="true"/><source src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458edc39e2312bae0996449_Copy-of-ChipTurns-1-transcode.webm" data-wf-ignore="true"/></video><div class="video-container w-container"><div class="hero-div center"><h1 data-w-id="01efa84b-d931-46d9-5e8e-a9afa1a952b9" style="opacity:0" class="h1-hero">Sampling of dermal Interstitial Fluid (dISF)</h1><h2 data-w-id="630c03ab-cc23-b9d9-6b63-696d3949c2f3" style="opacity:0" class="h2-hero center">Pioneering Hollow Microneedles</h2><div data-w-id="8c1215b0-3115-57b0-3826-e0e72d543a86" style="opacity:0" class="line center"></div><div data-w-id="11366be4-fbf9-6c50-68b4-979a350e79a9" style="opacity:0" class="text-main bold">Ascilion designs, develops, and manufactures products based on hollow microneedles for sampling of dermal interstitial fluid (dISF).<br/></div><div data-w-id="4b11628b-565a-8be0-9442-c180236b06aa" style="opacity:0" class="text-main bold">Access to endogenous and exogeneous biomolecules in dISF represents a unique opportunity for analysis of vital markers, health conditions and for research.</div><div data-w-id="eeb50eac-fbe6-a308-c80d-5c470d20b16f" style="opacity:0" class="text-main bold">Bringing biomolecules out of the body and into analysis is paramount for the next step in life science.</div><a data-w-id="3e654a8b-3e63-d879-1333-0ffa2a19d922" style="opacity:0" href="/contactus" class="_23_button w-button">Contact us</a></div></div></div><div class="_23-section-white"><div class="_50-50 w-container"><div class="_23-div-3block"><div data-w-id="1b5b704d-ff5a-8e35-8092-43ac01051189" style="opacity:0" class="content-div products"><a href="/products" class="linkblock-box w-inline-block"><div>Products</div></a><div class="dark-tone-div hide"></div></div><div data-w-id="ca62cabc-2cb9-3ba5-fbe5-9e6be33c8c91" style="opacity:0" class="content-div technology"><a href="/technology" class="linkblock-box w-inline-block"><div>Technology</div></a></div><div data-w-id="8fc65b89-dec7-6247-8eb4-9b964c407e5d" style="opacity:0" class="content-div applicationareas"><a href="/applications" class="linkblock-box w-inline-block"><div>Application areas</div></a></div></div></div></div><div class="_23-section-grid"><div class="w-layout-grid _2-grid nospace"><div id="w-node-_7b4802dc-45e3-f344-ec3d-fcf5adf1a771-f8939b64" data-w-id="7b4802dc-45e3-f344-ec3d-fcf5adf1a771" style="opacity:0" class="griddiv pelsa1"></div><div id="w-node-e5e72ab6-51b3-160e-acf7-e36f939c3a3f-f8939b64" data-w-id="e5e72ab6-51b3-160e-acf7-e36f939c3a3f" style="opacity:0" class="griddiv pelsa2"><h3 class="h3">Background</h3><div class="line smallred"></div><div class="text-main">Founded on the premise of radically improving healthcare, the team set out to develop hollow microneedles that can sample dermal interstitial fluid in a pain-free and easy to use way. After almost 10 years of development, the company is entering into numerous clinical trials with the aim of characterizing both the system and dISF itself.</div><a href="/about" class="textlink">Read more</a></div></div></div><div class="_23-section-productinfo space hide"><div class="_50-50 tight w-container"><h3 data-w-id="d997bd55-ac0e-ac5f-1602-a000190ddf9a" style="opacity:0" class="h3">The needle chip<br/></h3><div data-w-id="d5fd6d0c-73ba-32a5-6d3c-3c6a62795884" style="opacity:0" class="line smallred"></div><div data-w-id="f2fc65c9-404c-34a2-9b50-bb826f46ba96" style="opacity:0" class="text-main">Etched from pure silicon using MEMS technology, the needle chip is the core in Ascilion’s sampling products.</div><div class="_23-div-2block"><div data-w-id="e90eb2a4-bec9-2be0-08a6-448bf06cd573" style="opacity:0" class="_23-divbox-1"><div class="_23-bigtext">82</div><div class="text-main"><strong>Patents</strong></div></div><div data-w-id="9d49d138-acd9-7a1b-a10d-c6fbd3e4e758" style="opacity:0" class="_23-divbox-1"><div class="_23-bigtext">17</div><div class="text-main"><strong>Patent Families</strong></div></div></div></div></div><div class="_23-section-news"><div class="_50-50 space tight w-container"><h3 data-w-id="cec19bcc-39da-d62c-745f-d9b8676451fe" style="opacity:0" class="h3 center">News<br/></h3><div data-w-id="cec19bcc-39da-d62c-745f-d9b867645201" style="opacity:0" class="line smallred center"></div><div class="w-dyn-list"><div role="list" class="w-dyn-items"><div role="listitem" class="w-dyn-item"><div data-w-id="cb652e54-78b0-d5df-7005-838e27d05bdb" style="opacity:0" class="news-maindiv"><a data-w-id="79287590-67ae-90d9-21eb-85b65a1d3a20" href="#" class="news-link w-inline-block"><div class="news-text1">April 22nd </div><div class="news-text2">Ascilion announces enrollment of first patient in DIGIPREDICT-Bio-DE study</div></a><div class="news-hide"><div class="richtext-main w-richtext"><p><strong>STOCKHOLM, SWEDEN – Ascilion AB ("Ascilion") the leader in dermal interstitial fluid sampling for biomarker investigation announced today that the first patient has been enrolled in the DIGIPREDICT-Bio-DE study at the Deutsches Herzzentrum der Charité ("DHZC") in Berlin, Germany.</strong></p><p>Ascilion´s microneedle technology is used to extract dermal interstitial fluid (dISF), the fluid between cells in the skin. This fluid is rich in biomarkers, some of which are unique, and is a previously untapped source of health information.</p><p>Part of the pan-European DIGIPREDICT program, the study utilizes Ascilion´s technology to sample dISF, that is then used to validate a sensor platform developed to detect biomarkers relevant to cytokine storms and cardiovascular disease. </p><p>Last week the first ambulatory heart-failure patient was enrolled in the study at DHZC. The subject performed a cardiopulmonary exercise test (CPET) and both blood and dISF were sampled. By comparing biomarker concentrations in dISF and blood, biomarker sensors can be validated, and biomarker dynamics in dISF evaluated.</p><p>Dr Laurenz Kopp Fernandes, Senior Physician at DHZC, commented: <em>“The ability to sample dermal interstitial fluid means we now have really minimally-invasive access to established as well as to probably new biomarkers, which will potentially change the management of our patients. We are only now learning about how valuable the biomarker information contained in dISF can be. The enrollment of the first patient is an important step towards their investigation, and I am looking forward to the new insights we will gather in this important study.”</em></p><p>Simon Grant, CEO of Ascilion commented: <em>‘This project illustrates the potential for dISF sampling to take a central role within patient monitoring and management. Today, Ascilion has established relationships with global leaders in several industry segments. At the same time we have seen an increase in interest over the last 18 months that has been remarkable as researchers and industry learn about dISF and our technology.’</em></p><p>This project has received funding from the European Union’s Horizon 2020research and innovation programme under grant agreement No 101017915(DIGIPREDICT). www.digipredict.eu</p><p><strong>For further information visit </strong>www.ascilion.com <strong>or contact:</strong></p><p>Simon Grant, CEO</p><p>Tel: +46 72 887 43 99</p><p>E-post: info@ascilion.com <br/></p><p><strong><em>About Ascilion<br/></em></strong>Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s product PELSA is painless, quick, easy to use and leaves no residual mark on the skin. PELSA is available for research use and for pharmaceutical or cosmetic testing applications and is currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden and currently work with selected industrial partners and researchers. </p><p><strong><em>About DIGIPREDICT</em></strong></p><p>DIGIPREDICT – Digital Edge AI-deployed DIGItal Twins for PREDICTing disease progression and need for early intervention in infectious and cardiovascular diseases beyond COVID-19.</p><p>DIGIPREDICT is a pan-European research program bringing together scientific and technical excellence in multiple disciplines including informatics, engineering (embedded systems,sensors and wearables), medical science, translational science, ethical and regulatory frameworks. The consortium consists of in total nine members from academia, two large R&D institutes, two hospitals, three high-tech SMEs from five European countries. The project will develop Digital Twins to enable identification, monitoring, and screening of high-risk patients, and to provide them with the right supportive therapy based on referral decisions that can be personalized. A digital twin is a digital representation of an object or process from the real world in the digital world – and more specifically for the case of DIGIPREDICT – of a patient. </p><p>DIGIPREDICT will also develop wearables for early detection of infectious and cardiovascular diseases.</p><p> </p><p> </p><p>‍</p></div></div></div></div><div role="listitem" class="w-dyn-item"><div data-w-id="cb652e54-78b0-d5df-7005-838e27d05bdb" style="opacity:0" class="news-maindiv"><a data-w-id="79287590-67ae-90d9-21eb-85b65a1d3a20" href="#" class="news-link w-inline-block"><div class="news-text1">April 18, 2024</div><div class="news-text2">Ascilion technology judged top 1% of EU funded Innovations</div></a><div class="news-hide"><div class="richtext-main w-richtext"><p><strong>STOCKHOLM, SWEDEN – Ascilion AB ("Ascilion") the leader in dermal interstitial fluid sampling, announced today that Ascilion’s technology received the highest possible rating for <em>both </em>Market Creation Potential and Market Readiness from the European Commission’s Innovation Radar group. </strong></p><p>Ascilion´s microneedle technology is used to extract dermal interstitial fluid, the fluid between cells in the skin. This fluid is rich in biomarkers, some of which are unique, and is a previously untapped source of health information. Today, Ascilion works with global leaders in several industry segments to access and utilize this information.</p><p>As an essential part of the EU-funded pan-European DIGIPREDICT program, Ascilion has provided the sampling technology for the project. The Innovation project is titled ‘Minimal invasive system for dermal interstitial fluid (dISF) sampling and collection’.</p><p>Of the nearly 12,000 projects evaluated to date by the EU Innovation group, only 152 have received this highest level of evaluation, placing Ascilion in the top 1% of projects funded by EU. The evaluation is made up of two parts: Market creation potential and Market maturity. <br/><br/>Market creation potential was judged to be ’Very High’, the highest grade, and is an indication of the potential commercial impact the technology and products can have on the market. Market maturity was judged as ‘Market Ready’ which indicates that the products are ready to market, now.</p><p>Simon Grant, CEO of Ascilion commented: <em>‘We are extremely pleased that the EU has understood the potential and implications of our technology, and also how far the team has come with the products. To receive the highest rating in one classification is an achievement, to receive it in both is very rare. We believe that the potential for our products is broad and that they can open entirely new and exciting possibilities within monitoring and diagnostics that create significant value for industry while helping patients and consumers.’ </em></p><p>The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No101017915 (DIGIPREDICT). www.digipredict.eu</p><p>For further information visit www.ascilion.com or contact:</p><p>Simon Grant, CEO</p><p>Tel: +46 72 887 43 99</p><p>E-post: info@ascilion.com </p><p>‍</p></div></div></div></div><div role="listitem" class="w-dyn-item"><div data-w-id="cb652e54-78b0-d5df-7005-838e27d05bdb" style="opacity:0" class="news-maindiv"><a data-w-id="79287590-67ae-90d9-21eb-85b65a1d3a20" href="#" class="news-link w-inline-block"><div class="news-text1">March 25, 2024</div><div class="news-text2">Dermal ISF sampling abstract presented by Charité and Fraunhofer at the 2024 ADF meeting in Germany</div></a><div class="news-hide"><div class="richtext-main w-richtext"><p>For the third time Ascilion’s dermal ISF sampling solutions were presented at the annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) in Germany.</p><p>This year, researchers from the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, and Institute of Allergology (IA), Charité - Universitätsmedizin Berlin, presented the application of Ascilion’s hollow microneedles in a model of chronic inducible urticaria. </p><p>Read the abstract (on page 7):P014 - 15.1 <a href="https://www.adf-online.de/wp-content/uploads/EXD-Supplement-ADF-2024.pdf">“Application of hollow microneedles in a model of chronic inducible urticaria”</a> (Shi et al. 2024) </p><p>Ascilion ADF abstracts from 2024 and previous years can be found here: <a href="https://www.adf-online.de/adf-abstracts-2/abstract-book/" target="_blank">ADF Abstract Books</a> </p><p>‍</p><p>‍</p></div></div></div></div></div></div><a data-w-id="3230c02a-14ca-e5da-2f35-5b9657d6e2fa" style="opacity:0" href="/about" class="textlink center">More news</a></div></div><div class="_23-section-coretechnology space hide"><div class="_50-50 white w-container"><div class="_50"><h3 data-w-id="401e7839-73b7-e802-46fc-fac55dec3903" style="opacity:0" class="h3 white">The core technology<br/></h3><div data-w-id="401e7839-73b7-e802-46fc-fac55dec3906" style="opacity:0" class="line smallwhite"></div><div data-w-id="401e7839-73b7-e802-46fc-fac55dec3907" style="opacity:0" class="text-main">Ascilion’s core technology utilizes 3D processing of silicon on wafer scale with world leading expertise in MEMS design (Micro-Electro-Mechanical-Systems) and productization of semiconductor components and systems.</div><a data-w-id="893fa54f-a1b1-0503-a8b9-ebd8ca37db89" style="opacity:0" href="/technology" class="textlink white">Read more</a></div></div></div><div class="_23-section-white greyback"><div class="_50-50 w-container"><div class="_23-div-3block"><div data-w-id="7748ae38-cbea-1731-eb18-320c4e8972f8" style="opacity:0" class="content-div-icon"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458e3ab48724f036550e4e9_Pain-free.png" loading="lazy" alt="" class="icon-red"/><div>User Friendly</div><div class="text-main">The system and method enable user friendly sampling of dermal interstitial fluid. <br/>The sampling experience can be likened to gently touching Velcro.</div></div><div data-w-id="99c54baf-61f4-4780-438a-c0de9f2ecaea" style="opacity:0" class="content-div-icon"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458e3abea8876c5612a391c_Performance.png" loading="lazy" alt="" class="icon-red"/><div>Performance</div><div class="text-main">Multiple hollow microneedles sample on average one microliter of dermal interstitial fluid per minute, adequate volumes for modern analysis equipment in a short time span.</div></div><div data-w-id="16cf6497-451d-cbab-da45-7f4171be492b" style="opacity:0" class="content-div-icon"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/6458e3a98944dd5d752241eb_Easy-to-use.png" loading="lazy" alt="" class="icon-red"/><div>Easy to use</div><div class="text-main">We have designed a complete sampling system around a MEMS chip containing over 100 hollow microneedles.</div></div></div></div></div><div class="_23-section-white space"><div class="_50-50 center w-container"><div class="_23-div-3block"></div><h3 data-w-id="d0b78478-e549-8553-f74e-34a639f4ff37" class="h3 center">Get in touch<br/></h3><div data-w-id="d0b78478-e549-8553-f74e-34a639f4ff3a" class="line smallred center"></div><a data-w-id="d0b78478-e549-8553-f74e-34a639f4ff3d" href="/contactus" class="_23_button w-button">Contact us</a></div></div><div class="_23-section-grid hide"><div class="w-layout-grid _2-grid nospace"><div id="w-node-ab26235b-df96-f7dd-fec7-86bd6d6250c3-f8939b64" data-w-id="ab26235b-df96-f7dd-fec7-86bd6d6250c3" style="opacity:0" class="griddiv getintouchred"><h3 class="h3 white center">Get in touch<br/></h3><a href="/contactus" class="textlink white">Contact us</a></div><div id="w-node-ab26235b-df96-f7dd-fec7-86bd6d6250c4-f8939b64" data-w-id="ab26235b-df96-f7dd-fec7-86bd6d6250c4" style="opacity:0" class="griddiv joinourteam"><h3 class="h3 center">Join our team</h3><a href="/contactus" class="textlink">Contact us</a></div></div></div><div class="_23-section-footer"><div class="_50-50 w-container"><div class="_23-div-3block _23-footer"><div data-w-id="8908404d-4875-bd37-ab54-4f20088846b6" class="content-div-footer"><a href="/" aria-current="page" class="logotype-link w-inline-block w--current"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/645b62ec8c124f1151141509_ascilion_white.svg" loading="lazy" alt="" class="logotype-footer"/></a></div><div data-w-id="8908404d-4875-bd37-ab54-4f20088846b9" class="content-div-footer"><div class="_23-footer-headline"></div><a href="/" aria-current="page" class="textlink white _23-footer w--current">Home</a><a href="/products" class="textlink white _23-footer">Products</a><a href="/technology" class="textlink white _23-footer">Technology</a><a href="/applications" class="textlink white _23-footer">Application areas</a><a href="/about" class="textlink white _23-footer">About us</a><a href="/contactus" class="textlink white _23-footer">Contact</a></div><div data-w-id="8908404d-4875-bd37-ab54-4f20088846c6" class="content-div-footer"><div class="_23-footer-headline">Email</div><a href="mailto:info@ascilion.com" class="textlink white _23-footer">info@ascilion.com<br/></a><div class="_23-footer-headline">Post address</div><div class="text-main _23-footer">Ascilion AB, P.O. Box 1263<br/>SE-164 29 Kista, Sweden</div><div class="_23-footer-headline">Visiting address</div><div class="text-main _23-footer">Isafjordsgatan 22<br/>SE-164 40 Kista, Sweden</div></div><div data-w-id="8908404d-4875-bd37-ab54-4f20088846d8" class="content-div-footer"><div class="_23-footer-headline">Follow us</div><a href="https://is.linkedin.com/company/ascilion-ab" target="_blank" class="social-link w-inline-block"><img src="https://cdn.prod.website-files.com/5a2e5fada298f500011268d5/5a2e5fada298f500011268f8_social-09-white.svg" loading="lazy" alt="" class="social-pic"/></a></div></div><div data-w-id="8908404d-4875-bd37-ab54-4f20088846dd" class="_23-footer-copyright"><a href="/legal" class="_23-footerlink">Legal and regulatory disclaimer</a><br/>2023 © Copyright Ascilion </div></div></div><script src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=5a2e5fada298f500011268d5" type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script><script src="https://assets-global.website-files.com/5a2e5fada298f500011268d5/js/webflow.f7340586f.js" type="text/javascript"></script>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KJMMWVVG" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  </body></html>